Study uncovers a series of natural products that can inhibit the main protease of SARS-CoV-2

The fight against the COVID-19 pandemic is an international scientific challenge regarding the search for strategies to fight the viral infection and prevent its damaging consequences. Besides the vaccines and approved drugs by the health authorities, it is necessary to find new treatments to fight against the viral infection once this appears.

A study published in the Journal of Chemical Information and Modeling has identified a series of natural products able to inhibit Mpro, the main protease of SARS-CoV-2. Mpro is a non-structural protein with an essential role in the replication and transcription of this virus, and it is regarded as a potential therapeutic target, for its inhibition could prevent the virus from progressing.

The study is led by Professor Jaime Rubio Martínez, from the Faculty of Chemistry and the Institute of Theoretical and Computational Chemistry (IQTC) of the University of Barcelona, and it can shed light on the design of new therapeutic strategies to fight COVID-19. This new scientific advance is based on the use of in silico virtual screening, a computational analytical technique of molecules placed in databases to identify and select compounds that are candidates of potential pharmacological interest.

Virtual screening: searching for future drugs

Now, the clinical approach of COVID-19 is based on the symptomatic treatments through anti-inflammatory agents (for instance, dexamethasone or cytokine inhibitors) combined with antibiotics to treat secondary infections. Recently, the antiviral ritonavir has been approved, but there is still a need for new medicines. Within the context of global health, it is urgent to develop SARS-CoV-2-specific antiviral therapeutics and this led to the application of several strategies to identify bioactive compounds that can be used as therapeutic agents (including the available drugs and natural products). In this context, the virtual screening is a reliable, fast and efficient procedure for finding bioactive compounds of large chemical collections against a specific molecular target.

As part of the study, the team conducted a virtual screening of the natural product database Selleck -;a chemical library with nearly 2,000 compounds-; for a series of conformations of the SARS-CoV-2 Mpro characterized with a molecular dynamics study.

As a result, the study presents the characterization of the dynamic profile of Mpro protease in its apo shape through conventional simulations (cMD) and Gaussian accelerated molecular dynamics (GaMD) simulations, and it defines a series of representative structures.

These structures were later used to carry out the ensemble docking, a bioinformatic method that enables the prediction and calculation using computational techniques of the most favorable position of interaction between a ligand and its target protein. Then, they carried out an iterative procedure which increased the length of cMD of protein-ligand complexes and calculated the free binding energy to select the most promising candidates.

Having obtained the results, they selected eleven compounds and these were tested in vitro for their capability to inhibit Mpro protease. Among these, five SARS-CoV-2 antiviral candidates were identified as inhibitors of Mpro protease, using the natural products database.

Source:
Journal reference:

Rubio-Martínez, J., et al. (2021) Discovery of Diverse Natural Products as Inhibitors of SARS-CoV-2 Mpro Protease through Virtual Screening. Journal of Chemical Information and Modeling. doi.org/10.1021/acs.jcim.1c00951.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Study shows no developmental delays in toddlers post-COVID-19 infection